论文部分内容阅读
目的观察吉西他滨联合卡培他滨治疗多药耐药转移性乳腺癌的疗效及不良反应。方法 18例乳腺癌术后患者,经过蒽环类、紫杉醇类、长春碱类以及铂类治疗失败后改用吉西他滨1000 mg/m2静脉滴注第1天、第8天联合卡培他滨1250 mg/m2每日2次,第1~14天,口服,每3周为1个周期,至少应用2个周期后评价疗效和不良反应,并进行随访。结果 18例可评价患者中完全缓解1例,部分缓解10例,无变化3例,进展4例,总有效率为61.1%。不良反应主要为骨髓抑制、腹泻、口腔黏膜炎和手足综合征,但均可耐受。结论吉西他滨联合卡培他滨治疗多药耐药转移性乳腺癌疗效较好,安全性好,可成为安全有效的解救方案。
Objective To observe the efficacy and adverse reactions of gemcitabine and capecitabine in the treatment of multidrug-resistant metastatic breast cancer. Methods 18 cases of postoperative breast cancer patients after anthracycline, paclitaxel, vinblastine and platinum failed to use gemcitabine 1000 mg / m2 intravenous drip on the first day, the first 8 days combined capecitabine 1250 mg / m2 2 times a day, 1 to 14 days, orally, every 3 weeks for a period of at least 2 cycles after the evaluation of efficacy and adverse reactions, and follow-up. Results In 18 evaluable patients, complete remission was achieved in 1 case, partial remission in 10 cases, no change in 3 cases and progression in 4 cases, with a total effective rate of 61.1%. Adverse reactions were mainly bone marrow suppression, diarrhea, oral mucositis and hand-foot syndrome, but were tolerable. Conclusion The combination of gemcitabine and capecitabine in the treatment of multidrug-resistant metastatic breast cancer has better efficacy and safety, which can be a safe and effective rescue plan.